NCT02465229

Brief Summary

Biliary strictures present a diagnostic and therapeutic challenge to clinicians due to unsatisfied accuracy of sampling modality. The major problem is very difficult to discern malignant from non-malignant strictures, such as patients with primary sclerosing cholangitis (PSC). With the poor prognosis and high mortality rate of advanced stage of hepatopancreaticobiliary malignancies, early and accurate diagnosis impacts patients' outcome and possible surgical candidacy. Therefore, a pre-operative determination of malignancy to help plan appropriate treatment is highly desirable. Before 2000s, several diagnostic modalities, including laboratory tests, ultrasonography (US), computed tomography (CT) scan, cholangiography by percutaneous transhepatic cholangiography endoscopic (PTC) and endoscopic retrograde cholangiopancreatography (ERCP), and brushing cytology disclosed 13% to 24% false positive rate for suspicious malignant hilar strictures. Compared to recent studies, ERCP brushings still suffer from low sensitivity (41.6% ± 3.2% (99% CI)) and negative predictive value (58.0% ± 3.2% (99% CI)). In order to increase diagnostic accuracy, at least two sampling methods, including brushing cytology, biopsy, and fine-needle aspiration is therefore recommended. One article showed multimodal tissue-sampling (Brushing + Biopsy + Fine-needle aspiration) increased the sensitivity for diagnosis of malignant biliary stricture to 62%. However, no any literature demonstrate the best sequence of combined sampling modalities to yield the highest diagnostic accuracy. Besides, the role of stricture dilation before or after different tissue sampling modality is still uncertain. In this study, the investigators want to compare stricture dilation before or after multimodal tissue-sampling, including brush cytology, intraductal suction and forceps biopsy for the diagnosis of malignant biliary stricture and also assess which kind of the sequence of combined tissue-sampling modalities could offer the highest diagnostic accuracy.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2015

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 31, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 8, 2015

Completed
6 months until next milestone

Study Start

First participant enrolled

December 1, 2015

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

December 18, 2015

Status Verified

December 1, 2015

Enrollment Period

6 months

First QC Date

May 31, 2015

Last Update Submit

December 17, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Diagnostic accuracy of multimodal tissue-sampling before and after dilation

    Six months

Secondary Outcomes (1)

  • Diagnostic accuracy of individual tissue-sampling method

    Six months

Study Arms (1)

Diagnostic methods of indeterminate biliary stricture

EXPERIMENTAL
Procedure: Multimodal tissue-sampling methods before and after stricture dilation

Interventions

Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.

Diagnostic methods of indeterminate biliary stricture

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinically suspicious biliary stricture that required tissue sampling as medically indicated were considered for the study

You may not qualify if:

  • Biliary stricture caused by extra-luminal compression, such as pancreatic cancer and lymphadenopathy
  • Contraindication for ERCP study
  • Age younger than 20 years
  • Prior tissue sampling had yielded a diagnosis of malignancy
  • A guidewire could not be passed through the stricture
  • Less than 6-month follow-up was available for patients with negative tissue sampling

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Hsiu-Po Wang, Dr.

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hsiu-Po Wang, Dr.

CONTACT

Wei-Chih Liao, Dr.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2015

First Posted

June 8, 2015

Study Start

December 1, 2015

Primary Completion

June 1, 2016

Study Completion

December 1, 2016

Last Updated

December 18, 2015

Record last verified: 2015-12